KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,239 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,239 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $59,960.42. Following the completion of the sale, the insider owned 150,260 shares in the company, valued at approximately $4,023,962.80. This trade represents a 1.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ KALV opened at $26.79 on Thursday. The company’s 50-day simple moving average is $21.94 and its 200-day simple moving average is $17.65. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Needham & Company LLC lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.60.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Jefferies Financial Group Inc. acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $1,522,000. Hennion & Walsh Asset Management Inc. boosted its holdings in KalVista Pharmaceuticals by 93.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after purchasing an additional 165,236 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its holdings in KalVista Pharmaceuticals by 391.9% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after purchasing an additional 160,128 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.